



Lurasidone

Introduction

Second generation antipsychotics (sometimes referred to as 'atypical' antipsychotics) are a newer class of antipsychotic medication than first generation 'typical' antipsychotics. Second generation antipsychotics are effective for the positive symptoms of schizophrenia. It is sometimes claimed that they are more effective than first generation antipsychotics in treating the negative symptoms of schizophrenia, although the evidence for this is weak. Negative symptoms include a lack of ordinary mental activities such as emotional expression, social engagement, thinking and motivation, whereas positive symptoms include the experiences of perceptual abnormalities (hallucinations) and fixed, false, irrational beliefs (delusions).

Second generation antipsychotics may also cause less extra-pyramidal side effects. These include dyskinesias such as repetitive, involuntary, and purposeless body or facial movements, Parkinsonism (cogwheel muscle rigidity, pill-rolling tremor and reduced or slowed movements), akathisia (motor restlessness, especially in the legs, and resembling agitation) and dystonias such as muscle contractions causing unusual twisting of parts of the body, most often in the neck. These effects are caused by the dopamine receptor antagonist action of these drugs. One explanation for differences in producing these side effects is that high potency first generation antipsychotics are usually selective dopamine receptor antagonists with a high affinity for the dopamine receptor and they induce extrapyramidal effects by the blockade of these dopamine receptors. In contrast, second generation antipsychotics generally have a lower affinity for the dopamine receptor and also block serotonin receptors, both of which mechanisms may play a role in mitigating the effects of dopamine blockade. Amisulpride is an exception to other second generation antipsychotics in that it is a pure dopamine receptor antagonist, however it tends to block dopamine receptors more selectively in the

limbic system relative to the nigrostriatal system, which is the site responsible for inducing extrapyramidal symptoms. In addition to amisulpride, olanzapine and quetiapine also tend to selectively block dopamine receptors in the mesolimbic system but target serotonin receptors.

This table summarises overall group effectiveness of lurasidone, however individual treatment programs need to be tailored by trained clinicians as response - both in symptoms and adverse effects - can vary between individuals.

Method

Owing to the vast number of reviews on antipsychotics, we have prioritised information reported in the abstracts of Cochrane systematic reviews¹. This is because the Cochrane internal review process ensures a high level of scientific rigor and meta-analyses are usually conducted, giving treatment effect sizes. Data from the abstracts were supplemented from the full text when clarification was required. We have included only Cochrane reviews that have been published from the year 2000 to date to ensure the latest available evidence is presented. When multiple copies of reviews were found and/or when findings conflict, we present the most recent version and the most recent conclusions. Where no Cochrane review exists, other reviews with pooled data are included.

Evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation ([GRADE](#)) Working Group approach where high quality evidence such as that gained from RCTs may be downgraded to moderate or low if review and study quality is limited, if there is inconsistency in results, indirect comparisons, imprecise or sparse data and high probability of reporting bias. It may also be downgraded if risks associated with the intervention or other matter under review are high. Conversely, low quality evidence such as



Lurasidone

that gained from observational studies may be upgraded if effect sizes are large, there is a dose dependent response or if results are reasonably consistent, precise and direct with low associated risks². The resulting table represents an objective summary of the evidence, although the conclusions are solely the opinion of staff of NeuRA (Neuroscience Research Australia).

Results

We found two reviews that met our inclusion criteria^{3, 4}.



Lurasidone

Compared to placebo

Efficacy: Moderate to high quality evidence (large samples, some inconsistency, precise, direct) finds greater improvement in symptoms with lurasidone >20mg/d.

Adverse events: Moderate to high quality evidence finds more adverse events with lurasidone, including weight gain, nausea, vomiting, akathisia, dystonia, parkinsonism, somnolence, dizziness, and sedation.

Compared to second generation antipsychotics

Efficacy: Low quality evidence (unclear sample size, unable to assess consistency, imprecise or unable to assess, indirect) suggests no differences in response rates between lurasidone and brexpiprazole.

Adverse events: Low quality evidence finds less weight change, total cholesterol and low-density lipoprotein with lurasidone than with brexpiprazole.

[Ng-Mak D, Tongbram V, Ndirangu K, Rajagopalan K, Loebel A. Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: A network meta-analysis. Journal of Comparative Effectiveness Research 2018; 7.](#)

8 RCTs, N not reported.

There were no significant differences between groups in response rates (OR = 1.28, 95%CrI 0.88 to 1.87) or PANSS total (MD = -2.48, 95%CrI, -6.39 to 1.46) and clinical global impression (MD = -0.14, 95%CrI -0.35 to 0.07).

Risks

There was less weight change with lurasidone (MD = -0.69kg, 95%CrI -1.22 to -0.15), total cholesterol (MD = -7.60 mg/dl, 95%CrI -13.94 to -1.22), and low-density lipoprotein (MD = -6.58 mg/dl, 95%CrI -12.11 to -1.04).

Consistency in results[‡]

Unable to assess; no measure of consistency is reported.

Precision in results[§]

Imprecise or unable to assess MDs (not standardised).

Directness of results^{||}

Indirect (network meta-analysis)

[Zheng W, Cai DB, Yang XH, Li L, Zhang QE, Ng CH, Ungvari GS, Li XB, Ning YP, Xiang YT. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research 2018; 103: 244-51.](#)

Lurasidone was superior to placebo for total psychopathology (7 RCTs, N = 2,131, SMD = -0.34, 95%CI -0.48 to -0.20, I² = 54%), positive symptoms (6 RCTs, N = 1,853, SMD = -0.47, 95%CI -0.57 to -0.36, I² = 9%), negative symptoms (6 RCTs, N = 1,853, SMD = -0.34, 95%CI -0.45 to -0.22, I² =



Lurasidone

26%), general psychopathology (6 RCTs, N = 1,853, SMD = -0.36, 95%CI -0.48 to -0.24, I² = 30%), and depressive symptoms (N = 1,658, SMD = -0.17, 95%CI -0.33 to -0.02, I² = 51%).

These findings were not significant in a study using low dose lurasidone (20mg/d) and in studies with patients older than 38.6 years.

Meta-regression showed baseline symptom severity was not associated with the change in the general psychopathology.

Risks	Lurasidone resulted in more weight gain (N = 2,154, SMD = 0.15, 95%CI 0.06 to 0.24) and BMI (N = 1,543, SMD = 0.17, 95%CI 0.07 to 0.28), but the differences were not clinically significant. Lurasidone had less discontinuation due to any reason but was associated with more frequent vomiting, akathisia, dystonia, parkinsonism, somnolence, dizziness, sedation, nausea.
Consistency in results	Some inconsistency
Precision in results	Precise
Directness of results	Direct

Explanation of acronyms

CrI = credible interval, I² = the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance), MD = mean difference, mg/d = milligrams per day, N = number of participants, OR = odds ratio, p = statistical probability of obtaining that result (p < 0.05 generally regarded as significant), RCTs = randomised controlled trials, SMD = standardised mean difference, vs. = versus



Lurasidone

Explanation of technical terms

† Different effect measures are reported by different reviews.

Weighted mean difference scores refer to mean differences between treatment and comparison groups after treatment (or occasionally pre to post treatment) and in a randomised trial there is an assumption that both groups are comparable on this measure prior to treatment. Standardised mean differences are divided by the pooled standard deviation (or the standard deviation of one group when groups are homogenous) which allows results from different scales to be combined and compared. Each study's mean difference is then given a weighting depending on the size of the sample and the variability in the data. 0.2 represents a small effect, 0.5 a medium effect, and 0.8 and over represents a large effect¹.

Odds ratio (OR) or relative risk (RR) refers to the probability of a reduction (< 1) or an increase (> 1) in a particular outcome in a treatment group, or a group exposed to a risk factor, relative to the comparison group. For example, a RR of 0.75 translates to a reduction in risk of an outcome of 25% relative to those not receiving the treatment or not exposed to the risk factor. Conversely, a RR of 1.25 translates to an increased risk of 25% relative to those not receiving treatment or not having been exposed to a risk factor. A RR or OR of 1.00 means there is no difference between groups. A medium effect is considered if $RR > 2$ or < 0.5 and a large effect if $RR > 5$ or $< 0.2^5$. InOR stands for logarithmic OR where a lnOR of 0 shows no difference between groups. Hazard ratios measure the effect of an explanatory variable on the hazard or risk of an event.

Correlation coefficients (eg, r) indicate the strength of association or relationship between variables. They are an indication of

prediction, but do not confirm causality due to possible and often unforeseen confounding variables. An r of 0.10 represents a weak association, 0.25 a medium association and 0.40 and over represents a strong association. Unstandardised (b) regression coefficients indicate the average change in the dependent variable associated with a 1 unit change in the independent variable, statistically controlling for the other independent variables. Standardised regression coefficients represent the change being in units of standard deviations to allow comparison across different scales.

‡ Inconsistency refers to differing estimates of effect across studies (i.e. heterogeneity or variability in results) that is not explained by subgroup analyses and therefore reduces confidence in the effect estimate. I^2 is the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) - 0% to 40%: heterogeneity might not be important, 30% to 60%: may represent moderate heterogeneity, 50% to 90%: may represent considerable heterogeneity and over this is considerable heterogeneity. I^2 can be calculated from Q (chi-square) for the test of heterogeneity with the following formula¹;

$$I^2 = \left(\frac{Q - df}{Q} \right) \times 100\%$$

§ Imprecision refers to wide confidence intervals indicating a lack of confidence in the effect estimate. Based on GRADE recommendations, a result for continuous data (standardised mean differences, not weighted mean differences) is considered imprecise if the upper or lower confidence limit crosses an effect size of 0.5 in either



Lurasidone

direction, and for binary and correlation data, an effect size of 0.25. GRADE also recommends downgrading the evidence when sample size is smaller than 300 (for binary data) and 400 (for continuous data), although for some topics, these criteria should be relaxed⁶.

|| Indirectness of comparison occurs when a comparison of intervention A versus B is not available but A was compared with C and B was compared with C, which allows indirect comparisons of the magnitude of effect of A versus B. Indirectness of population, comparator and/or outcome can also occur when the available evidence regarding a particular population, intervention, comparator, or outcome is not available and is therefore inferred from available evidence. These inferred treatment effect sizes are of lower quality than those gained from head-to-head comparisons of A and B.



Lurasidone

References

1. CochraneCollaboration (2008): Cochrane Handbook for Systematic Reviews of Interventions. Accessed 24/06/2011.
2. GRADEWorkingGroup (2004): Grading quality of evidence and strength of recommendations. *British Medical Journal* 328: 1490.
3. Ng-Mak D, Tongbram V, Ndirangu K, Rajagopalan K, Loebel A (2018): Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: A network meta-analysis. *Journal of Comparative Effectiveness Research* 7.
4. Zheng W, Cai DB, Yang XH, Li L, Zhang QE, Ng CH, *et al.* (2018): Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. *Journal of Psychiatric Research* 103: 244-51.
5. Rosenthal JA (1996): Qualitative Descriptors of Strength of Association and Effect Size. *Journal of Social Service Research* 21: 37-59.
6. GRADEpro (2008): [Computer program]. Jan Brozek, Andrew Oxman, Holger Schünemann. *Version 32 for Windows*